Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYSB89)

DTT Name Epiregulin (EREG)
Synonyms l=Epiregulin; Proepiregulin; EPR
Gene Name EREG
DTT Type
Clinical trial target
 [1]
BioChemical Class
Growth factor
UniProt ID
EREG_HUMAN
TTD ID
T79157
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MTAGRRMEMLCAGRVPALLLCLGFHLLQAVLSTTVIPSCIPGESSDNCTALVQTEDNPRV
AQVSITKCSSDMNGYCLHGQCIYLVDMSQNYCRCEVGYTGVRCEHFFLTVHQPLSKEYVA
LTVILIILFLITVVGSTYYFCRWYRNRKSKEPKKEYERVTSGDPELPQV
Function
Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Ligand of the EGF receptor/EGFR and ERBB4.
KEGG Pathway
ErbB signaling pathway (hsa04012 )
Reactome Pathway
PI3K events in ERBB4 signaling (R-HSA-1250342 )
SHC1 events in ERBB4 signaling (R-HSA-1250347 )
Nuclear signaling by ERBB4 (R-HSA-1251985 )
PIP3 activates AKT signaling (R-HSA-1257604 )
GRB2 events in ERBB2 signaling (R-HSA-1963640 )
PI3K events in ERBB2 signaling (R-HSA-1963642 )
Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530 )
RAF/MAP kinase cascade (R-HSA-5673001 )
SHC1 events in ERBB2 signaling (R-HSA-1250196 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY3016859 DM7T1CR Chronic kidney disease GB61 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43.